Company intelligence / Profile preview

Albireo Pharma

Boston, Massachusetts, United Statesbylvay.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Bylvay (odevixibat), a non-systemic ileal bile-acid transport inhibitor, is the first approved treatment for pruritus in PFIC. It has completed Phase 3 trials for Alagille syndrome and is being studied in biliary atresia. Additional candidates are advancing through early clinical stages targeting rare pediatric and adult liver diseases

Therapeutic areas: Rare DiseasesGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Albireo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albireo Pharma.

Explore the full profile